<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 71.3</label>
 <caption>
  <p>Influenza prevention in households with postexposure prophylaxis (PEP)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="3">Study</th>
    <th rowspan="3">Drug (age of contacts)</th>
    <th rowspan="3">Season (virus)</th>
    <th rowspan="3">Index case treated</th>
    <th colspan="2">Influenza A illness in contacts</th>
    <th rowspan="3">PEP efficacy (%)</th>
   </tr>
   <tr>
    <th colspan="2">No./total evaluable (%)</th>
   </tr>
   <tr>
    <th>Active</th>
    <th>Control</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Galbraith et al. [
     <xref ref-type="bibr" rid="CR208">208</xref>]
    </td>
    <td>Amantadine (≥2 years)</td>
    <td>1967–1968 (A/H2N2)</td>
    <td>No</td>
    <td>0/91 (0 %)</td>
    <td>12/90 (13 %)</td>
    <td>100</td>
   </tr>
   <tr>
    <td>Bricaire et al. [
     <xref ref-type="bibr" rid="CR300">209</xref>]
    </td>
    <td>Rimantadine (≥1 year)</td>
    <td>1988–1989 (A/not stated)</td>
    <td>No</td>
    <td>8/151
     <sup>a</sup> (5 %)
    </td>
    <td>26/150
     <sup>a</sup> (17 %)
    </td>
    <td>70</td>
   </tr>
   <tr>
    <td>Monto et al. [
     <xref ref-type="bibr" rid="CR209">210</xref>]
    </td>
    <td>Zanamivir (≥5 years)</td>
    <td>2000–2001 (A/H3N2, B)</td>
    <td>No</td>
    <td>12/661 (2 %)</td>
    <td>55/630 (9 %)</td>
    <td>82</td>
   </tr>
   <tr>
    <td>Welliver et al. [
     <xref ref-type="bibr" rid="CR210">211</xref>]
    </td>
    <td>Oseltamivir (≥13 years)</td>
    <td>1998–1999 (A/H3N2, B)</td>
    <td>No</td>
    <td>4/493 (1 %)</td>
    <td>34/462 (72 %)</td>
    <td>89</td>
   </tr>
   <tr>
    <td>Galbraith et al. [
     <xref ref-type="bibr" rid="CR211">212</xref>]
    </td>
    <td>Amantadine (≥2 years)</td>
    <td>1968–1969 (A/H3N2)</td>
    <td>Yes</td>
    <td>5/43 (12 %)</td>
    <td>6/42 (145 %)</td>
    <td>6</td>
   </tr>
   <tr>
    <td>Hayden et al. [
     <xref ref-type="bibr" rid="CR25">25</xref>]
    </td>
    <td>Rimantadine (≥1 year)</td>
    <td>1987–1989 (A/H3N2, A/H1N1)</td>
    <td>Yes</td>
    <td>11/61 (18 %)</td>
    <td>10/54 (19 %)</td>
    <td>3</td>
   </tr>
   <tr>
    <td>Hayden et al. [
     <xref ref-type="bibr" rid="CR212">213</xref>]
    </td>
    <td>Zanamivir (≥5 years)</td>
    <td>1998–1999 (A/H3N2, B)</td>
    <td>Yes</td>
    <td>7/414 (2 %)</td>
    <td>40/423 (9 %)</td>
    <td>82</td>
   </tr>
   <tr>
    <td>Hayden et al. [
     <xref ref-type="bibr" rid="CR213">214</xref>]
    </td>
    <td>Oseltamivir (≥1 year)</td>
    <td>2000–2001 (A/H3N2, B)</td>
    <td>Yes</td>
    <td>11/400 (3 %)</td>
    <td>40//392 (10 %)</td>
    <td>73</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <sup>a</sup>Clinical influenza
  </p>
 </table-wrap-foot>
</table-wrap>
